Cargando…

Stencil Printing—A Novel Manufacturing Platform for Orodispersible Discs

Stencil printing is a commonly used printing method, but it has not previously been used for production of pharmaceuticals. The aim of this study was to explore whether stencil printing of drug containing polymer inks could be used to manufacture flexible dosage forms with acceptable mass and conten...

Descripción completa

Detalles Bibliográficos
Autores principales: Wickström, Henrika, Koppolu, Rajesh, Mäkilä, Ermei, Toivakka, Martti, Sandler, Niklas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023198/
https://www.ncbi.nlm.nih.gov/pubmed/31906316
http://dx.doi.org/10.3390/pharmaceutics12010033
_version_ 1783498194318000128
author Wickström, Henrika
Koppolu, Rajesh
Mäkilä, Ermei
Toivakka, Martti
Sandler, Niklas
author_facet Wickström, Henrika
Koppolu, Rajesh
Mäkilä, Ermei
Toivakka, Martti
Sandler, Niklas
author_sort Wickström, Henrika
collection PubMed
description Stencil printing is a commonly used printing method, but it has not previously been used for production of pharmaceuticals. The aim of this study was to explore whether stencil printing of drug containing polymer inks could be used to manufacture flexible dosage forms with acceptable mass and content uniformity. Formulation development was supported by physicochemical characterization of the inks and final dosage forms. The printing of haloperidol (HAL) discs was performed using a prototype stencil printer. Ink development comprised of investigations of ink rheology in combination with printability assessment. The results show that stencil printing can be used to manufacture HAL doses in the therapeutic treatment range for 6–17 year-old children. The therapeutic HAL dose was achieved for the discs consisting of 16% of hydroxypropyl methylcellulose (HPMC) and 1% of lactic acid (LA). The formulation pH remained above pH 4 and the results imply that the drug was amorphous. Linear dose escalation was achieved by an increase in aperture area of the print pattern, while keeping the stencil thickness fixed. Disintegration times of the orodispersible discs printed with 250 and 500 µm thick stencils were below 30 s. In conclusion, stencil printing shows potential as a manufacturing method of pharmaceuticals.
format Online
Article
Text
id pubmed-7023198
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70231982020-03-12 Stencil Printing—A Novel Manufacturing Platform for Orodispersible Discs Wickström, Henrika Koppolu, Rajesh Mäkilä, Ermei Toivakka, Martti Sandler, Niklas Pharmaceutics Article Stencil printing is a commonly used printing method, but it has not previously been used for production of pharmaceuticals. The aim of this study was to explore whether stencil printing of drug containing polymer inks could be used to manufacture flexible dosage forms with acceptable mass and content uniformity. Formulation development was supported by physicochemical characterization of the inks and final dosage forms. The printing of haloperidol (HAL) discs was performed using a prototype stencil printer. Ink development comprised of investigations of ink rheology in combination with printability assessment. The results show that stencil printing can be used to manufacture HAL doses in the therapeutic treatment range for 6–17 year-old children. The therapeutic HAL dose was achieved for the discs consisting of 16% of hydroxypropyl methylcellulose (HPMC) and 1% of lactic acid (LA). The formulation pH remained above pH 4 and the results imply that the drug was amorphous. Linear dose escalation was achieved by an increase in aperture area of the print pattern, while keeping the stencil thickness fixed. Disintegration times of the orodispersible discs printed with 250 and 500 µm thick stencils were below 30 s. In conclusion, stencil printing shows potential as a manufacturing method of pharmaceuticals. MDPI 2020-01-01 /pmc/articles/PMC7023198/ /pubmed/31906316 http://dx.doi.org/10.3390/pharmaceutics12010033 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wickström, Henrika
Koppolu, Rajesh
Mäkilä, Ermei
Toivakka, Martti
Sandler, Niklas
Stencil Printing—A Novel Manufacturing Platform for Orodispersible Discs
title Stencil Printing—A Novel Manufacturing Platform for Orodispersible Discs
title_full Stencil Printing—A Novel Manufacturing Platform for Orodispersible Discs
title_fullStr Stencil Printing—A Novel Manufacturing Platform for Orodispersible Discs
title_full_unstemmed Stencil Printing—A Novel Manufacturing Platform for Orodispersible Discs
title_short Stencil Printing—A Novel Manufacturing Platform for Orodispersible Discs
title_sort stencil printing—a novel manufacturing platform for orodispersible discs
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023198/
https://www.ncbi.nlm.nih.gov/pubmed/31906316
http://dx.doi.org/10.3390/pharmaceutics12010033
work_keys_str_mv AT wickstromhenrika stencilprintinganovelmanufacturingplatformfororodispersiblediscs
AT koppolurajesh stencilprintinganovelmanufacturingplatformfororodispersiblediscs
AT makilaermei stencilprintinganovelmanufacturingplatformfororodispersiblediscs
AT toivakkamartti stencilprintinganovelmanufacturingplatformfororodispersiblediscs
AT sandlerniklas stencilprintinganovelmanufacturingplatformfororodispersiblediscs